Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cas

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

The Merger Agreement contains certain customary termination rights for the Company and Parent. Subje

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​de

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarini

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “C

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients rega

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and ma

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.59) per share. This is a 96.67 percent decr

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and ma

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

ZW191 is an ADC engineered to target FRα, a protein expressed in several tumor types, including appr

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare a

Evercore ISI Group analyst Jonathan Miller maintains Zymeworks (NASDAQ:ZYME) with a Outperform an

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai

Stifel analyst Stephen Willey maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price t

Leerink Partners analyst Andrew Berens maintains Zymeworks (NASDAQ:ZYME) with a Outperform and ra

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HE

- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare

Truist Securities analyst Asthika Goonewardene initiates coverage on Zymeworks (NASDAQ:ZYME) with

Wells Fargo analyst Eva Fortea Verdejo upgrades Zymeworks (NASDAQ:ZYME) from Equal-Weight to Over

Citizens analyst Reni J. Benjamin initiates coverage on Zymeworks (NASDAQ:ZYME) with a Market Out

B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and rais

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Equal-Weight and

Stifel analyst Stephen Willey maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price t

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai

Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainabl

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting p

GOOG: 5% | Alphabet Inc shares are trading higher after Berkshire Hathaway disclosed a new stake in